Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
PHASE2CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
April 30, 2003
Study Completion Date
July 31, 2006
Conditions
B-CLL
Interventions
DRUG
alemtuzumab
Trial Locations (1)
SE-171 76
Dept. of Hematology, Karolinska University Hospital, Stockholm
All Listed Sponsors
collaborator
Schering Nordiska AB
UNKNOWN
lead
Karolinska University Hospital
OTHER
NCT00162851 - Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter